Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Summary not available.
Summary not available.